If you have a promising biological asset but aren’t ready to take on the permanent financial overhead of full-time, senior C-suite executives, that is when you bring us in. We provide high-level strategic support without a heavy permanent payroll. We progress your assets through critical development steps, scaling our involvement up or down based strictly on your immediate milestones.

Our core technical and operational expertise is heavily focused on biologics and advanced RNA modalities. Backed by over 15 years of frontier hands-on experience, we specialize in guiding complex biologics programs, including RNA-based therapeutics, recombinant proteins, and ADCs, from early laboratory discovery through physical scale-up, cGMP CDMO alignment, and IND-readiness strategy.

We act as your independent scientific due diligence arm to protect your venture capital. We audit early-stage laboratory platforms, analyze raw preclinical data packages, and evaluate the physical scalability of a startup’s molecule before a deal closes. We cut through the computational or laboratory hype to ensure that the asset you are funding possesses a realistic, compliant pathway to market.

We act as a bilateral bridge between Western and Asian life science ecosystems. We help Western companies navigate regional compliance and secure fast-track placement into premier Asian incubation hubs like HKSTP or Singapore frameworks. Simultaneously, we advise Asian biotechnology entities looking to scale globally, preparing their data packages to meet strict Western regulatory standards and successfully enter the European market.

Data sovereignty and IP protection are our highest priorities. Before we look at a single piece of your data or platform architecture, we execute a comprehensive mutual Non-Disclosure Agreement (NDA). All files shared with EvolBio Limited are managed within secure, isolated environments. We never use public AI models or open networks to process your proprietary discoveries, your IP remains strictly confidential and entirely yours.

We don't offer generic high-level slides or abstract theoretical advice. I bring real-world, hands-on experience running technical laboratory workflows and commercial CDMO operations, having transitioned complex biologics from early discovery straight to IND-readiness. At EvolBio, we bridge the deep gap between laboratory reality and investor expectations, giving early-stage startups and venture capital funds practical, action-oriented strategy that directly de-risks assets and protects runway.

We avoid rigid, high-fee retainers that drain early-stage startup budgets. We offer flexible, milestone-based advisory structures. Whether you need a short, focused sprint to de-risk an upcoming investor pitch deck, a comprehensive asset due diligence audit, or fractional R&D leadership for an IND filing, you only utilize and pay for our expertise when your project demands it.